RR Baliga MD, MBA
@rrbaliga.bsky.social
Zerlasiran, a small-interfering RNA (siRNA), significantly reduces Lp(a) (~85%)
Muvalaplin, an oral small-molecule inhibitor, reducing levels by up to 85.8%.
Both drugs were well-tolerated in Phase 2 trials, with further studies needed to evaluate CV reduction.
youtu.be/xEcp4whuc6o?...
Muvalaplin, an oral small-molecule inhibitor, reducing levels by up to 85.8%.
Both drugs were well-tolerated in Phase 2 trials, with further studies needed to evaluate CV reduction.
youtu.be/xEcp4whuc6o?...
Novel Therapeutics for Reduction of Lipoprotein (a)
YouTube video by MasterMedFacts
youtu.be
March 24, 2025 at 2:27 PM
Zerlasiran, a small-interfering RNA (siRNA), significantly reduces Lp(a) (~85%)
Muvalaplin, an oral small-molecule inhibitor, reducing levels by up to 85.8%.
Both drugs were well-tolerated in Phase 2 trials, with further studies needed to evaluate CV reduction.
youtu.be/xEcp4whuc6o?...
Muvalaplin, an oral small-molecule inhibitor, reducing levels by up to 85.8%.
Both drugs were well-tolerated in Phase 2 trials, with further studies needed to evaluate CV reduction.
youtu.be/xEcp4whuc6o?...